Details of the Drug Reposition

General Information of This Drug (ID: DM14NKM)

Drug Name
Triiodothyronine   DM14NKM
Synonyms
liothyronine; triiodothyronine; 3,3',5-Triiodo-L-thyronine; 6893-02-3; Liothyronin; Tresitope; 3,5,3'-triiodothyronine; L-Liothyronine; O-(4-Hydroxy-3-iodophenyl)-3,5-diiodo-L-tyrosine; 3,5,3'-Triiodo-L-thyronine; triothyrone; Liothyroninum; Lyothyronine; Liotironina; T3; L-T3; 3,3',5-Triiodothyronine; Triiodo-L-thyronine; 3,5,3'TRIIODOTHYRONINE; L-3,5,3'-Triiodothyronine; T3 (amino acid); T3 (Hormone); L-3,3',5-TriioDOThyronine; Liothyronine [INN:BAN]; Li; Liothyronine
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Euthyroid goiter DISLRPYJ 5A01.1 Approved [1]
------------------------------------------------------------------------------------
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Coronavirus Disease 2019 (COVID-19) DISM7GNX 1D6Y Phase 2 [2]
------------------------------------------------------------------------------------

References

1 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 076923.
2 ClinicalTrials.gov (NCT04348513) Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection. U.S. National Institutes of Health.